Skip to main content

Generic Roszet Availability

Last updated on Jul 6, 2022.

Roszet is a brand name of ezetimibe/rosuvastatin, approved by the FDA in the following formulation(s):

ROSZET (ezetimibe; rosuvastatin calcium - tablet;oral)

  • Manufacturer: ALTHERA PHARMS
    Approval date: March 23, 2021
    Strength(s): 10MG;EQ 5MG BASE [RLD], 10MG;EQ 10MG BASE [RLD], 10MG;EQ 20MG BASE [RLD], 10MG;EQ 40MG BASE [RLD]

Has a generic version of Roszet been approved?

An Authorized Generic version of Roszet has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.

List of authorized generic versions:

  • rosuvastatin and ezetimibe ORAL TABLET 10; 5.2 mg/1; mg
    SCOV3 LLC
    NDC Code: 821200125
  • rosuvastatin and ezetimibe ORAL TABLET 10; 10.4 mg/1; mg
    SCOV3 LLC
    NDC Code: 821200126
  • rosuvastatin and ezetimibe ORAL TABLET 10; 20.8 mg/1; mg
    SCOV3 LLC
    NDC Code: 821200127
  • rosuvastatin and ezetimibe ORAL TABLET 10; 41.7 mg/1; mg
    SCOV3 LLC
    NDC Code: 821200128

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Roszet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,376,470

    Patent expiration dates:

    • May 1, 2033
      ✓ 
      Patent use: TREATMENT OF HYPERLIPIDEMIA
      ✓ 
      Drug product
  • Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
    Patent 9,763,885
    Issued: September 19, 2017
    Assignee(s): Althera Laboratories Ltd.

    The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubricants, colorants and combinations thereof.

    Patent expiration dates:

    • May 1, 2033
      ✓ 
      Patent use: TREATMENT OF HYPERLIPIDEMIA
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.